Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX) and Boston Scientific (BSX)
Analysts maintained Buy ratings on Evaxion Biotech (EVAX) and Boston Scientific (BSX). Thomas Flaten set a $9.00 target for EVAX, while Matthew Taylor set a $60.00 target for BSX. Both stocks have consensus Buy ratings with significant upside potential according to TipRanks.
How this was made
The 30-second read
Why it matters
Both companies receive higher price targets, but no new corporate events are disclosed.
Market read
Provides modest sentiment boost for EVAX and BSX; limited trading impact.
What to watch
Potential dilution from future financing or clinical trial setbacks.
Background
Analyst rating updates for two healthcare companies published on the same day.
Ticker impact
Analyst Thomas Flaten maintains a Buy rating with a $9 price target; H.C. Wainwright reiterates Buy with $16 target.
Modest upside as investors price in higher targets.
Both analysts raise targets, but no new corporate event; impact limited to sentiment.
Analyst Matthew Taylor assigns a Buy rating with a $60 target; consensus remains Strong Buy with $62.09 target.
Potential modest rally if market reacts to higher target.
Rating aligns with consensus; limited new catalyst beyond analyst opinion.
Market effects
Reinforces bullish sentiment in healthcare biotech and medical device subsectors.
Minimal; primarily U.S. investors.
Low; no broader macro or sector shift.
Counterpoint
Analyst upgrades may be premature without new product or trial data.
Key entities
- AnalystThomas Flaten
Lake Street analyst covering EVAX.
- AnalystMatthew Taylor
Jefferies analyst covering BSX.
